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utilizing engineered nucleases in combination with induced
pluripotent stem cell (iPSC) technology. Here, we report tran-
scription activator-like effector nuclease (TALEN)-mediated
reincorporation of Arg1 exons 7 and 8 in iPSCs derived from
arginase-1-deficient mice possessing Arg1D alleles lacking these
terminal exons. The edited cells could be induced to differen-
tiate into hepatocyte-like cells (iHLCs) in vitro and were subse-
quently used for transplantation into our previously described
(Sin et al., PLoS ONE 2013) tamoxifen-inducible Arg1-Cre argi-
nase-1-deficient mouse model. While successful gene-targeted
repair was achieved in iPSCs containing Arg1D alleles, only
minimal restoration of urea cycle function could be observed
in the iHLC-transplanted mice compared to control mice,
and survival in this lethal model was extended by up to a
week in some mice. The partially rescued phenotype may be
due to inadequate regenerative capacity of arginase-1-express-
ing cells in the correct metabolic zones. Technical hurdles exist
and will need to be overcome for gene-edited iPSC to iHLC
rescue of arginase-1 deficiency, a rare urea cycle disorder.Received 17 October 2017; accepted 17 November 2017;
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Engineered sequence-specific nucleases, such as zinc finger nucleases
(ZFNs), transcription activator-like effector nucleases (TALENs), and
CRISPRs have been exploited for modeling diseases and developing
novel therapeutic applications. These programmable nucleases can
be broadly classified into two categories based on their mode of
DNA recognition: ZFNs and TALENs achieve specific DNA binding
via protein-DNA interactions, whereas CRISPR/Cas9 is directed to
specific target sites by a single guide RNA that base-pairs directly
with the target DNA sequence, as well as by protein-DNA interac-
tions between Cas9 protein and the protospacer-adjacent motif
(PAM).1–4
Among these gene-editing technologies, TALENs exhibit a high de-
gree of targeting specificity and flexibility.5 They recognize and cleave
nearly any given DNA sequence with high efficiency in a broad range
of organisms, including human cells, rodents, zebrafish, and
plants.6–15 Moreover, the low off-target effects and reduced
nuclease-associated cytotoxicities make TALENs great tools for
gene engineering in cells.10,16 These site-specific nucleases are engi-122 Molecular Therapy: Nucleic Acids Vol. 10 March 2018 ª 2017 The
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FokI with the TALE DNA-binding domain specifically designed to
target a desired genomic site for gene modifications.3,5 TALEs bind
specifically to DNA targets via a central repeat domain and activate
transcription of their targets by means of a C-terminal transcriptional
activation domain.17 The binding domain is a series of customized
34-residue TALE repeat arrays in “two amino acids for one base”
(“repeat variable di-residue”; RVD) recognition code, providing
DNA-binding specificity.18,19 Double-strand breaks (DSBs) occur
when two independent TALENs, working in heteromeric pairs,
bind to opposite strands of the target site separated by a 12- to
20-bp spacer region, thereby allowing dimerization of FokI and cleav-
age of the target locus.3,5 This cleavage can then be resolved by cellular
DNA repair, either by error-prone non-homologous end joining
(NHEJ), which has the potential to introduce mutations at the site
of the DSB, or by template-dependent homologous recombination
(also termed homology-directed repair [HDR]) for precise genetic
modification. Depending on the donor DNA template design, the
repair mechanism can be initiated for gene replacement, single-nucle-
otide substitutions, or large-scale deletions.1
Arginase deficiency is a rare urea cycle disorder with hyperarginine-
mia and profound neurological impairment as hallmark features.20
Arginase-1-deficient mouse models have been created, and they
exhibit a profound lethal phenotype approximately 2 weeks after birth
in the global knockout (KO) mice or after induction of tamoxifen-
induced gene KO in adult mice (about 2 weeks after induced
KO).21–23 Recently, we generated induced pluripotent stem cells
(iPSCs) from our inducible arginase-1-deficient mouse model car-
rying a deletion of Arg1 exons 7 and 8 (Arg1D), which results in
defective function of arginase-1.24 We showed that the deletion was
repaired using CRISPR/Cas9, in combination with an excisable
piggyBac transposon system to target corrective sequences to
the endogenous Arg1 locus. In the current study, we report onAuthor(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. TALEN-Mediated Gene Targeting in Arg1D
Mouse iPSCs
(A) Schematic diagram showing the site of Arg1 gene
modification using TALEN set 7/8. The TALEN 7/8 pair
was designed to target intron 6 of Arg1. Each TALEN arm
consists of a DNA-binding domain with repeat variable di-
residues (RVDs) corresponding to DNA binding sequence
proceeded by a 50 T nucleotide and a 17-bp spacer region
containing a BspHI recognition site (highlighted in yellow)
to assay activity. TALE repeat domains are colored to
indicate the identity of the RVD. Site-specific double-
stranded breaks (DSBs) are generated upon dimerization
of fused FokI endonucleases. (B) Electroporation to deliver
7 mg of each TALEN and pMax-GFP into cells to assess
transfection efficiency. Images were acquired 24 hr post-
electroporation. Scale bars, 95 mm. (C) Surveyor nuclease
assay for detection of NHEJ-induced indels resulting from
DSBs. The cleavage products were shown as extra bands
(between 162 and 186 bp) indicated by the arrows.
Mutation frequencies (indels %) were calculated by
measuring the band intensities. (D) BspHI digestion
results. The cut products were shown as extra bands
(169 bp + 183 bp). (E) Sequencing data from PCR am-
plicons of TALEN-modified genomic DNA showing a few
examples of NHEJ-mediated indel mutations at the
desired location. The wild-type sequence is shown above
with the TALEN-binding sites in red. Deleted bases are
indicated by colons, and inserted bases are shown by
lowercase letters in blue. The net change in length caused
by each indel mutation is to the right of each sequence.
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successful differentiation to hepatocyte-like cells (HLCs) coupled
with piggyBac transposon selection technology for seamless genetic
manipulation, followed by secondary expansion to propagate the re-
paired iPSC-derived HLCs (named iHLCs hereafter). The genetically
repaired iHLCs were transplanted to restore arginase-1 expression in
Arg1D mice, and survival of the arginase-1-deficient mice was
extended by up to a week in somemice. Although an elevation in argi-
nase-1 expression was observed in the iHLC-transplanted mice, urea
cycle function was still considerably lower than in wild-type control
mice, thus necessitating further refinement in gene-edited iHLC
transplantation cell therapy.
RESULTS
Design of TALEN-Targeting Strategy for Correcting Arg1-
Deficient (Arg1D) iPSCs
We designed a TALEN pair targeting intron 6 of the Arg1 locus at a
region adjacent to the position targeted previously by CRISPR/
Cas9.24 Each monomer contains an array of RVDs to bind the target
DNA sequences (Figure 1A). The TALEN expression constructs
showed good transfection efficiency when introduced into mouse
iPSCs by electroporation (Figure 1B). Surveyor nuclease cleavage to
detect NHEJ events of PCR products from the target region produced
two bands in the 162- to 186-bp range, with insertion or deletion
(indel) frequencies up to 18% in mouse iPSCs (Figure 1C), similar
to that with CRISPR/Cas9.24 The TALEN pair target sites were
selected to utilize a BspHI restriction site located within the spacerregion to determine editing efficiency. The loss of the BspHI recogni-
tion sequence was demonstrated by the presence of uncleaved PCR
products compared to the control (Figure 1D). Sequencing results
confirmed that the TALENs induced DSBs at the predetermined
position in the Arg1 locus (Figure 1E).
TALEN-Mediated Reincorporation of Deleted Exons via HDR
By taking advantage of iPSCs and their propensity for unlimited self-
renewal capacity and their differentiation potential, we examined a
TALEN-mediated targeted knockin approach for deleted exons 7
and 8 of Arg1 in Arg1D iPSCs. TALEN-expressing vector delivery,
together with a linearized targeting vector, which consists of exons
7 and 8 cDNA fused to an RFP monomeric-encoding segment with
piggyBac inverted terminal repeats (ITRs) flanking a PGK-Puro-TK
cassette, was performed (Figure 2A). An HDR stimulatory com-
pound, L-755,507, was added into the culture to enhance TALEN-
mediated HDR efficiency.25 Upon cleavage by TALENs and
subsequent HDR with the repair template, exons 7 and 8 should be
reincorporated into the Arg1 locus. Eleven puromycin-resistant
iPSC colonies were obtained and screened for proper targeting by
PCR. We designed two primer pairs spanning the junction between
the insert and endogenous sequence in both homologous arms as
indicated in Figure 2A to examine correct integration. Of the 11
clones analyzed, two were correctly targeted (clones #T4 and #T10;
efficiency of 18.2%) for both PCR primer sets (Figure 2B). These
two clones were subjected to piggyBac-mediated excision of the inte-
grated selection cassette. Upon ganciclovir selection, PCR screeningMolecular Therapy: Nucleic Acids Vol. 10 March 2018 123
Figure 2. Footprint-free TALEN-Mediated Correction of Arg1D Mouse iPSCs
(A) Schematic of strategy used for TALEN-mediated reincorporation of Arg1 exons 7 and 8 via homology-directed repair in combination with piggyBac transposon meth-
odology. Green triangle denotes the target site of TALEN 7/8 in intron 6 of Arg1. Black arrows indicate primers for PCR-based screening to confirm the selected clones. The
remnant LoxP left from the initial Cre-excision of exons 7 and 8 would be removed upon targeting vector integration. The characteristic “footprint” TTAA sequence at the site
of transposon excision is shown. PBx, piggyBac transposase; T2A, viral sequence for ribosomal skipping; Puro, puromycin; ITR, inverted terminal repeat; TK, thymidine
kinase. (B) Representative gel images showing integration-specific PCR of puromycin-resistant single-cell clones derived from Arg1D iPSC after TALEN treatment. Each
homology arm was amplified independently by PCR. Amplicon sizes of the left and right arm were 1,530 and 1,233 bp, respectively. The clones indicated by an asterisk are
correctly targeted with integrated selection cassette and corrective sequence in the desired position at the Arg1 locus. (C) PCR-based excision screening. A table shows
primer combination to uniquely identify different alleles after piggyBac excision and negative selection by ganciclovir. (D) A representative gel of different banding patterns and
corresponding genotypes. Amplicon sizes of the repaired and targeted alleles were 668 bp and 530 bp, respectively. PBx-excised clones are indicated by asterisks.
(E) Footprint sequencing analysis of transposon-free repair clones. TTAA target sites are boxed.
Molecular Therapy: Nucleic Acidsof 17 ganciclovir-resistant colonies revealed three with biallelic repair
(Figure 2C). All three completely repaired clones were from the #T4
line (Figure 2D). Our TALEN-mediated targeting experiments
demonstrated HDR knockin efficiency comparable to that of the
CRISPR/Cas9 system.24 Sequence analysis showed the presence of a
single TTAA sequence26 at the site of transposon excision in the re-
paired cell lines (clones #T4–7, #T4–12, #T4–17), an evidence for
scarless removal of selectable marker cassettes following successful
HDR (Figure 2E).
Transplantation of Repaired iHLCs Extends Survival in Some
Mice after Induced Arginase-1 Loss of Expression
To facilitate iPSC-mediated ex vivo gene therapy, efficient differ-
entiation into the proper cell type after gene repair is essential.
Considering the challenges in coaxing iPSCs to mature functional124 Molecular Therapy: Nucleic Acids Vol. 10 March 2018hepatocytes in culture in our recent work,24 we attempted to test
whether iHLCs can mature after transplantation and if Arg1 gene ed-
iting could lead to the restoration of functional arginase in the liver.
Repaired clones (#T4–7 and #T4–12) were subjected to hepatic differ-
entiation using a stepwise protocol, which includes hepatic specifica-
tion, hepatoblast formation, and iHLC expansion (Figure 3A). At the
end of the 25-day differentiation protocol, 2 million iHLCs were
transplanted into Arg1-Cre mice via splenic administration. More
importantly, two cycles of retrorsine treatment followed by partial
hepatectomy was performed prior to transplantation to stimulate
engraftment and regenerative capacity.27 Mice were then allowed to
recover for 15 weeks, at which time the 5-day sequential tamoxifen-
induced global Arg1 gene disruption was carried out. Kaplan-Meier
survival curves of Arg1D mice versus iHLC-transplanted mice began
to diverge on day 14 after the last dose of tamoxifen. In fact, the
Figure 3. Generation of Hepatocyte-like Cells from
Repaired Mouse iPSCs for Transplantation
(A) Schematic diagram showing time allocated for TALEN-
mediated correction, clone screening, and hepatic dif-
ferentiation prior to transplantation. Scale bars, 95 mm. (B)
Kaplan-Meier survival curves of tamoxifen-induced Arg1D
mice (n = 3) and Arg1D mice injected with repaired iHLCs
(n = 10). (C) Representative agarose gel of PCR geno-
typing using genomic DNA from tail biopsies to confirm
the deletion of exons 7 and 8. Arg1-Cre mice exhibited
two bands at 1.2 kb and 252 bp (indicative of intact exons
7 and 8), while Arg1D mice only showed a single band at
195 bp. (D) PCR to confirm the presence of the repaired
allele in liver samples obtained from iHLC transplanted
(668 bp). Cultured repaired iHLCs were used as a positive
control, while liver from an untreated Arg1-Cre mouse
served as negative control.
www.moleculartherapy.orgsurvival of the iHLC-transplanted mice was extended up to an extra
week (day 22 post-tamoxifen) compared to the Arg1D mice, which
died at the usual time point (around 14 days post-tamoxifen) from
a wasting phenotype21–23 (Figure 3B). Successful excision of exons
7 and 8 of Arg1 induced by tamoxifen administration in experimental
mice was verified by PCR genotyping of tail samples for the diagnostic
band of 195 bp (Figure 3C). Using primers flanking the Arg1 and RFP
domains, liver tissue samples obtained from iHLC-transplanted mice
yield bands at 668 bp, indicating the presence of the repaired allele
(Figure 3D).
Recovery of Arginase Expression in Livers Repopulated with
Transplanted Repaired iHLCs
Real-time qPCR analysis was carried out to evaluate Arg1 mRNA in
liver using primers in the region encoded by exons 7 and 8. Our
data show significantly increased Arg1 transcripts in liver tissues of
iHLC-transplanted mice compared to non-transplanted mice, con-
firming the restoration of full-length Arg1 mRNA expression after
gene correction (Figure 4A). However, the level was still distinctly
lower than in livers obtained from wild-type mice. After excision of
the ITR-flanked PGK-Puro-TK cassettes by piggyBac transposase
(PBx), the C-terminal Arg1-RFP should be expressed under the con-
trol of the endogenous Arg1 promoter. Hence, hepatocytes expressing
fusion protein Arg1-RFP were analyzed by western blot analysis.
While wild-type liver samples showed a strong immunoreactive
37 kDa Arg1 band, appreciable amounts of Arg1-RFP fusion product
were detected in the iHLC-transplanted mice (Figure 4B). Next, we
performed immunohistochemical staining in liver sections to detect
restored arginase-1 protein and examine repopulation efficiency. As
shown in Figure 4C, the results clearly demonstrate that transplanta-
tion of the edited iHLCs improves arginase-1 expression as compared
to Arg1D mice. Moreover, the transplanted iHLCs did not develop
into hyperplastic nodules. Interestingly, scattered distribution ofarginase-1 expression was observed throughout the regenerated liver
parenchyma in the iHLC-transplanted mice with no signs of colocal-
ization with glutamine-synthetase surrounding the central veins. As
in sections from wild-type and Arg1D mice, immunostaining of liver
slices obtained from iHLC-transplantedmice showed only the hepatic
marker albumin (Alb) expression and lack of immature hepatocyte-
specific marker alpha-fetoprotein (Afp) expression, providing evi-
dence of in vivo maturation of iHLCs. Together, our data indicate
that genetically corrected mouse iPSCs can express the Arg1 protein
once they differentiate into mature hepatocytes. Finally, we assessed
the potential of restored Arg1 for improving functional enzyme activ-
ity. Although iHLC-transplanted mice showed significantly higher
arginase-1 activity when compared to Arg1D mice, the level is still
considerably low compared to normal activity (Figure 5A). No signif-
icant differences were observed in blood arginine levels in the iHLC-
transplanted mice compared to Arg1D mice at both baseline (4 days
post-tamoxifen administration) and humane endpoint, when argi-
nine levels are substantially increased (Figure 5B).
DISCUSSION
In this study, we demonstrate TALEN-mediated gene editing to
repair the dysfunctional Arg1D allele in iPSCs, in concert with trans-
plantation-based studies. Our data reveal that TALEN-mediated site-
specific genomemodification inmouse iPSCs was similar in efficiency
with the CRISPR/Cas9 system.24 Our application of TALEN-medi-
ated gene repair highlights the feasibility and potential for gene-edit-
ing strategies using engineered cell therapies, albeit with modest
improvement in survival after iHLC transplantation in the argi-
nase-1 KO mouse model. qPCR and western blot analyses verified
the presence of repaired cells expressing arginase-1. Nevertheless,
transplantation of repaired iHLCs only resulted in about 5% repopu-
lation of livers, and the lifespan of the transplantedmice could only be
modestly extended by up to a week in some mice. The transplantedMolecular Therapy: Nucleic Acids Vol. 10 March 2018 125
Figure 4. Arg1 Expression Profile in Liver Tissues
(A) Real-time qPCR analysis of Arg1 gene expression in
liver tissues. The Ct values of all genes were normalized to
the Ct values of GAPDH. The y axis represents the fold
change of gene expression compared with wild-type liver
using the comparative threshold method (2DDCt). Values
are mean ± SEM for n = 3–10. Statistical significance
between groups was determined by Student’s t test
(*p < 0.05). (B) Western blot analysis of total liver extracts
(20 mg/well). Arg1 protein expression was evaluated by
immunoblotting with an anti-Arg1 antibody (C-terminal)
and anti-red fluorescent protein (RFP) antibody. a-tubulin
was used as loading control. (C) Immunostaining for Arg1
(Alexa Fluor 488, green), alpha-fetoprotein (Afp), albumin,
and glutamine synthetase (GS) (Alexa Fluor 594, red)
in serial liver sections from representative mice. Scale
bars, 95 mm.
Molecular Therapy: Nucleic Acidscells failed to fully recapitulate the normal liver distribution of argi-
nase-1 in the correct metabolic zones, hence leading to marginal
urea cycle function and elevation of blood arginine.
The major challenges highlighted by this study are the low rates of
engraftment and the lack of hepatocyte repopulation in the correct
liver zones. There are two main metabolic zonations in the liver.
Metabolic activities such as glycolysis, lipogenesis, and xenobiotic
disposal preferentially localized in perivenous (PV) areas encode
glutamine synthetase, GLT1 (a glutamate transporter), and RHBG
(an ammonia transporter).28 In contrast, key enzymes of the urea
cycle such as ARG1 and carbamoyl-phosphate synthase (CPS1) are
preferentially expressed in the periportal (PP) regions.
Intrasplenic transplantation of hepatocytes, which we employed in
this study, was reported to facilitate cell integration in PP locations.29
We also performed partial hepatectomy to create a growth advantage
for transplanted cells.27 However, we could not achieve optimum
engraftment and functional regeneration for long-term therapeutic
effects. We are not certain as to why transplanted edited cells were
distributed in a scattered pattern and not in clusters as seen in our
previous work30 and by others,31 since similar protocols were used
for transplantation studies. Further work is required to understand
these phenomena. Taking our current study and previous observa-
tions30 together, we reasoned that proper integration of transplanted
cells in the correct metabolic zone of liver parenchyma is critical for
enhancing the metabolic urea cycle capacity of the liver. The success126 Molecular Therapy: Nucleic Acids Vol. 10 March 2018of the hepatocyte infusion protocol is likely to
depend on engraftment of sufficient numbers
of hepatocytes in the PP loci for optimum argi-
nase-1 enzyme activity. There are several ques-
tions to be addressed: (1) What is the optimal
differentiation stage of iHLCs to achieve the
highest level of engraftment and urea cycle
function? (2) As the remaining hepatocytes after
partial hepatectomy still have extensive prolifer-ative potential, will they constrain competitive advantage for the
transplanted cells? (3) Is there senescence or any immunogenic
response to the newly corrected gene product of transplanted iHLCs?
One of the major concerns of iPSC development is the potential
tumorigenicity of iPSCs and their progeny.32 However, recent find-
ings using in vitro differentiated iPSC-derived cells have sparked opti-
mism over their therapeutic potential. There was no evidence of
immune rejection of iPSCs that have matured to an adult fate,
including endothelial cells, hepatocytes, and neuronal cells upon
transplantation into syngeneic mice.33,34 The discrepancies between
those studies may be attributable to different iPSC lines used in their
experiments. In this regard, it should be noted that in vitro differen-
tiated gene-edited cells may have distinctive immunogenicity due to
genetic manipulation and their long culture time. It remains to be
determined whether iHLCs derived from gene-edited iPSCs used
in our transplantation studies were immunogenic and if transient
immunosuppression is required following transplant. (4) Can zonal
regeneration of gene-edited hepatocytes be manipulated to improve
therapeutic efficacy? Several signaling pathways have been identified
to direct zonal organization including Wnt/b-catenin35,36 and its
antagonistic pathway, Ras/MAPK/Erk.37 Further investigation is
needed to refine our current understanding in shaping desired meta-
bolic zonation.
In summary, this report demonstrates another successful application
of gene editing in iPSCs. Despite the lack of efficient metabolic func-
tional repair after transplantation, the application of gene correction
Figure 5. Analysis of Hepatic Function of iHLC-
Transplanted Mice
(A) Arg1 enzyme activity in livers of iHLC-transplanted
mice measured at endpoint compared to wild-type and
non-transplanted Arg1D mice. (B) Measurement of blood
arginine levels at baseline (4 days after tamoxifen admin-
istration) and humane endpoint. Values are mean ± SEM
for n = 3–10. Statistical significance between groups was
determined by Student’s t test (*p < 0.05).
www.moleculartherapy.orginto HLCs might still be a realistic goal for ex vivo gene therapy of
liver diseases with further experimental optimization. To our knowl-
edge, these results represent the first description of transplantation
using cells derived from HDR-mediated repair of iPSCs for argi-
nase-1 deficiency. The development of efficient targeted gene editing
using TALENs and CRISPR/Cas9 systems could open exciting new
avenues for arginase-1 gene therapy.
MATERIALS AND METHODS
Mice and Cell Source
The inducible Arg1-deficient mouse strain (herein referred to as
Arg1-Cre mice), derived from parental strains Arg1flox (JAX strain
008817, C57BL/6-Arg1tm1Pmu/J) and CreERT2 (JAX strain 008463,
B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J) were injected intraperitone-
ally (i.p.) on 5 sequential days with tamoxifen to induce global
Arg1 deficiency (herein referred to as Arg1D mice) as previously
described.21 All procedures were reviewed and approved by the
Queen’s University Animal Care Committee (approval #Funk-
2011-048-R1-A4) and conformed to the Guidelines of the Canadian
Council on Animal Care. Arg1D mouse iPSCs were generated from
Arg1D PMEFs as described in a previous study.24
Design and Assembly of TALENs Targeting the Mouse
Arg1 Gene
A pair of TALENs (left TALEN 50-GCTTTGTGTGCGAGT-30,
right TALEN 50-TCCTGACATTCCTGTCA-30) were designed and
assembled to target a region close to exon 6 in the Arg1 gene using
the GoldyTALEN scaffold method.38 The TALEN target site com-
prises binding sites for two TALE-FokI fusion proteins that are
each preceded by a T at the 50 end and a unique restriction enzyme
(BspHI) recognition site within the spacer region. Specificity of
TALENs was examined using NCBI Primer-BLAST. Potential off-
target sites were assessed in silico using the Paired Target Finder
tool on the TAL Effector Nucleotide Targeter 2.0 web interface to
scan the mouse genome for sequences containing mismatches
within the TALEN pair target site.39 The repeat variable di-peptide
(RVD)-containing units for TAL-7 (NN HD NG NG NG NN NG
NN NG NN HD NN NI NN NG) and TAL-8 (NG NN NI HD
NI NN NN NI NI NG NN NG HD NI NN NN NI) were assembled
using the Golden Gate approach.40 After assembly, the RVDs werecloned into the pC-Goldy TALEN destination vector for expression
in mammalian cells.
Functional Evaluation of TALEN Cutting Efficiency
Arg1D iPSCs (3  106) were electroporated with equal amounts of
each TALEN plasmid DNA (7 mg each) to induce double-stranded
breaks (Gene Pulser System, 250 V, 500 mF, 0.4 cm cuvettes)
(Bio-Rad, Mississauga, ON, Canada). Genomic DNA from the elec-
troporated cells was isolated 2 days later. The genomic region sur-
rounding the TALEN target site (within intron 6 and 30 UTR
of the Arg1 gene) was amplified with Phusion high-fidelity
DNA polymerase (NEB, Ipswich, MA). Primers used were as fol-
lows: forward 50-CTAACCGTCATTAACTTCACTCTG-30, reverse
50-GCACTGTCTAAGCCCGAGAGTATC-30. Purified PCR prod-
ucts were subjected to a re-annealing process using a step gradient
(95C–25C over 30 min) to enable heteroduplex formation. For
mismatch cleavage assays, the annealed products were treated
with Surveyor nuclease (Transgenomics, Omaha, NE), and resultant
cleavage products (two bands at 162–185 bp and 167–185 bp) were
analyzed in 8% Tris-borate-EDTA polyacrylamide gels. The indel
efficiency was quantified based on the relative band intensities
measured using Quantity One Software (Bio-Rad, Mississauga,
ON, Canada). The indel percentage was calculated using the
following formula: 100  (1  (1  (b + c)/(a + b + c))1/2), wherein
a is the intact band and b and c represent the Surveyor nuclease
digestion products. The PCR products were also assessed for gene
modification by BspHI (NEB, Ipswich, MA) digestion, which gave
rise to 183 and 169 bp fragments. To confirm TALEN-mediated
gene modification, PCR amplicons were subcloned into pCR 2.1-
TOPO TA vector (Invitrogen, Carlsbad, CA) and individual col-
onies were subjected to sequence analysis.
TALEN-Mediated Gene Targeting and Excision of Selection
Markers Using PBx
A custom-designed repair targeting vector24 with Arg1 homology
arms, which consists of exons 7 and 8 cDNA fused to the coding
sequence of monomeric RFP, a hybrid PGK-EM7 promoter, a
positive-negative drug resistance cassette carrying a puromycin-
thymidine kinase resistance gene, and a self-cleaving 2A peptide
(T2A), all flanked by the piggyBac transposon ITRs (Transposagen,Molecular Therapy: Nucleic Acids Vol. 10 March 2018 127
Molecular Therapy: Nucleic AcidsLexington, KY) was introduced into the cells together with TALEN
plasmids to initiate HDR. The targeting vector was linearized with
NotI (NEB, Ipswich, MA) prior to electroporation. L-755,507
(5 mM, Tocris BioScience, Minneapolis, MN) was also added to the
cells to increase the efficiency of donor incorporation.25 Puromycin
treatment (1 mg/mL) was initiated 4 days after electroporation to
identify cells that successfully integrated the targeting vector. The
resulting colonies were picked on day 14 and expanded on puromy-
cin-resistant mitotically-inactivated PMEFs (iPMEFs) for further
characterization. PCR genotyping was carried out for both left and
right arms independently using LongAmp Taq DNA polymerase
(NEB, Ipswich, MA), with one of the two PCR primers designed
to anneal outside the region spanned by both homology arms to
ensure on-target integration. Primers were as follows: left arm for-
ward (LA-F) 50-GTCTGCAGAGATTCGGAAGGTAAC-30, reverse
(LA-R) 50-CTGACTAGGGGAGGAGTAGAAGGT-30; right arm
forward (RA-F) 50- CCGTAATGCAGAAGAAGACC-30, reverse
(RA-R) 50-GGCTATTGAAGATTTAACATTTGG-30. The selection
cassette was removed by introducing PBx (Transposagen, Lexington
KY) into the puromycin-resistant cells. Four days after piggyBac exci-
sion, ganciclovir selection (2 mM, Cayman Chemical, Ann Arbor, MI)
was carried out to eliminate the cells that have residual vector
expression. After a 2-week selection period, colonies were picked
and expanded on gelatin-coated dishes without feeder cells. Genomic
DNA was extracted and subjected to PCR-based screening of
transposon-excised clones using primers as follows: PBx-F 50-TCA
CAGGACTTACAGTGATC-30; PBx-R 50-CATGAACTCCTTGAT
GACG-30 and PB3-P2-Forward 50-GCGACGGATTCGCGCTATT
TAGAAA-30 (transposon-specific primer). PCR products resulting
from the removal of the selection cassette were sequenced to confirm
the intended genetic modification and the presence of the TTAA
sequence at the excised site.26
Differentiation of Mouse iPSCs into HLCs In Vitro
TALEN-mediated gene-edited cells were differentiated into HLCs
using a modified stepwise protocol as previously described.24 In
brief, mouse iPSCs were trypsinized into single-cell suspensions
and resuspended in advanced RPMI containing 10% fetal bovine
serum (FBS) (Wisent, St-Bruno, Quebec, Canada), 100 ng/mL acti-
vin A (R&D Systems, Minneapolis, MN), and 50 ng/mL Wnt3a
(R&D Systems, Minneapolis, MN). One million cells per well
were seeded into 12-well plates coated with 2% Matrigel (BD Biosci-
ences, Mississauga, ON, Canada) and incubated at 37C/5% CO2 for
direct definitive endoderm (DE) induction. FBS was reduced to
0.2% on the following day until day 5. On day 6–10, the medium
was replaced with hepatic commitment medium (advanced RPMI,
2% FBS, 50 ng/mL BMP4 (PeproTech, Montreal, Quebec, Canada),
20 ng/mL FGF-2, (PeproTech, Montreal, Quebec, Canada). On day
11-15, the medium was replaced with advanced RPMI containing
2% FBS, and 20 ng/mL hepatocyte growth factor (HGF; PeproTech,
Montreal, Quebec, Canada) to promote the expansion of early
hepatic progenitor cells. Cells were maintained in advanced
RPMI supplemented with 2% FBS, 20 ng/mL HGF, 20 ng/mL
Oncostatin M (R&D System, Minneapolis, MN), 50 nM dexameth-128 Molecular Therapy: Nucleic Acids Vol. 10 March 2018asone (Sigma-Aldrich, St. Louis, MO), and 1 insulin-transferrin-
selenium (Corning, Corning, NY) for at least 10 days prior to
transplantation.
iHLC Transplantation Studies
Twelve-week-old female Arg1-Cre mice were used as recipients. The
mice were conditioned with retrorsine (70 mg/kg i.p., twice at 2 week
intervals) (Sigma-Aldrich, St. Louis, MO) prior to transplantation.
Two-thirds partial hepatectomy27 was performed after the last retro-
rsine dose to create a selective growth advantage for transplanted
cells. In brief, mice were anesthetized with isoflurane/O2 and
20mg/kg subcutaneously (s.c.) of Tramadol for pre-surgery analgesia.
The left lobe and median lobes were ligated with a silk filament at the
base before resection. Two million iHLCs (donor cells) were sus-
pended in 100 mL of Hanks’ Balanced Salt Solution (HBSS) and
injected slowly over 20–30 s into the lower pole of the spleen. All
operations were performed on a heating pad with sterile surgical tech-
niques. Immediately after surgery, mice received 1 mL of warmed
saline and 2.5 mg/kg Meloxicam. Five hundred microliters of saline,
Tramadol, and Meloxicam were administered for the next 3 days.
The following experimental groups were defined: group 1-wild-type
(n = 3), group 2-Arg1 knockout (n = 3), and group 3-transplantation
of repaired iHLCs (n = 10). Fifteen weeks later, allowing sufficient
time for donor cell engraftment, the 5-day sequential tamoxifen-
induced Arg1 KO regimen was carried out.21 Changes in body weight
of mice were carefully monitored daily during the experimental
period. Humane endpoints were defined as body weight loss
of >15% relative to the weight at the time of final tamoxifen admin-
istration, accompanied by hunched posture. The endpoint took place
between days +11 to +14 with the mean at day +13.21,30 Hence, life-
span extension of mice that underwent iHLC transplantation was
recorded from this time point (day +13).
PCR Genotyping
Genomic DNA from tail biopsies was extracted by standard protocols
and subjected to PCR for genotyping using primer sets (Integrated
DNA Technologies, Coralville, IA) as follows: F1 50-TGCGAGTT
CATGACTAAGGTT-30, R1 50-AAAGCTCAGGTGAATCGG-30,
and R2 50-GCACTGTCTAAGCCCGAGAGTATC-30. Cycle parame-
ters were as follows: denaturation at 94C for 30 s, annealing at 64.5C
for 1 min, and elongation at 72C for 1 min for 35 cycles.
Liver Engraftment Analysis by Immunohistochemistry
Liver tissues were collected immediately at the time mice were sacri-
ficed. Paraformaldehyde-fixed and paraffin-embedded mouse liver
sections (4 mm thick) were stained following standard immunohis-
tochemical protocols, performing heat-induced antigen retrieval
(10 mM citrate buffer [pH 6.0], 0.02% Tween 20) before incubation
with primary antibodies. IHC analysis (rather than direct fluores-
cence detection of red fluorescent protein [RFP]) was preferred as
livers exhibit high autofluorescence. Primary antibodies used in this
study were as follows: Arg-1 (Abcam, Cambridge, MA, #ab91279,
1:200), glutamine synthetase (Abcam, Cambridge, MA, #ab64613,
1:200), Alb (Abcam, Cambridge, MA, #ab19196, 1:400), Afp (Novus
www.moleculartherapy.orgBiologicals, Littleton, CO, #NBP-762755, 1:200). Fluorescent second-
ary antibodies, Alexa Fluor 488 goat anti-rabbit immunoglobulin
G (IgG) (Molecular Probes, Eugene, OR, #A-11068, 1:400), Alexa
Fluor 594 goat anti-mouse IgG (Molecular Probes, Eugene, OR,
#A-11005, 1:400), and Texas Red goat anti-rabbit IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA, #111-075-144,
1:200) were used for primary antibody detection. Slides were then
dehydrated and mounted with ProLong Gold antifade reagent
with DAPI (Invitrogen, Carlsbad, CA). Visualization was performed
with a fluorescent microscope (Leica, DM IRB, Richmond Hill, ON).
Gene Expression Analysis
Liver tissues were pulverized in liquid nitrogen prior to RNA extrac-
tion. Total RNA was extracted with TRIzol reagent (Invitrogen,
Carlsbad, CA), followed by RNA cleanup using a GeneJET RNA
Purification Kit (Fisher Scientific, Unionville, ON, Canada) and
treated with DNase I (1 mg/mL, Invitrogen, Carlsbad, CA) as per the
manufacturer’s instructions. RNA quality was assessed with the
RNA 6000 Nano Kit (Agilent Technologies, Mississauga, ON, Can-
ada). cDNA was synthesized from 1 mg of total RNA using an iScript
cDNA synthesis kit (Bio-Rad, Mississauga, ON, Canada). qPCR was
performed using a thermal cycler (Applied Biosystems Model 7500)
with SYBR Green PCR master mix (Bio-Rad, Mississauga, ON,
Canada). Melting curves were performed on completion of the cycles
to ensure absence of nonspecific products. Primers (Integrated
DNA Technologies, Coralville, IA) were designed to span exon-
exon boundaries to avoid the amplification of genomic DNA. Primer
sets were as follows: Arginase-1 (accession number, NM_007482),
50-ACAAGACAGGGCTCCTTTCAG-30 (sense), 50-TGAGTTCC
GAAGCAAGCCAA-30 (antisense); and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (accession number: NM_001289726),
50-CATGGCCTTCCGTGTTCCTA-30 (sense), 50-ATGCCTGCTT
CACCACCTTCT-30 (antisense). Relative gene expression was calcu-
lated using the comparative threshold method (2DDCT) and is
presented as fold-change of transcripts for target genes normalized
to the expression of housekeeping gene GAPDH. Gene expression
values in wild-type hepatocytes were set to 1.
Western Blot Analysis
Liver tissues were pulverized in liquid nitrogen and homogenized in
ice-cold radioimmunoprecipitation assay (RIPA) buffer (Millipore,
Bedford, MA), including protease inhibitor cocktail (Roche, Missis-
sauga, ON, Canada). Twenty-micrograms of centrifuged, clarified
protein samples were subjected to western blot analysis and probed
with rabbit polyclonal anti-Arg1 antibody (C-terminal) (Abcam,
Cambridge, MA, #ab91279, 1:10,000), mouse monoclonal anti-RFP
antibody (Rockland Immunochemicals, Limerick, PA, #200-301-
3795, 1:2,000), and mouse polyclonal anti-a-tubulin antibody
(Sigma-Aldrich, St. Louis, MO, #T5168, 1:5,000) used as loading
control. Immunoreactive proteins were detected using horseradish
peroxidase-conjugated goat anti-rabbit or anti-mouse secondary
antibody (Sigma-Aldrich, St. Louis, MO, 1:5,000) and visualized by
enhanced chemiluminescence detection (GEHealthcare, Mississauga,
ON, Canada).Arginase Activity Assay and Biochemical Analysis
Arginase activities of all samples were assayed as described previ-
ously.21,30 One unit of activity is defined as 10 nmol urea/mg protein.
Whole-blood samples were obtained from the submandibular vein on
day 4 and 14 following the final tamoxifen (or vehicle) injection and
humane endpoint (for mice surviving beyond day 14 post-tamoxifen
administration). Drops of blood were collected into microcapillary
tubes prior to transfer onto the Whatman 903 filter paper cards
(GE Healthcare, Mississauga, ON, Canada). Sample preparation
was based on the method described previously30 prior to analysis
by mass spectrometry.
Statistical Analysis
All experiments were performed at least in three biological replicates.
Survival curves were computed in each group of mice using the
Kaplan-Meier method and compared across groups using the log
rank test. All results are expressed as mean ± standard error of
mean (SEM). Statistical analysis was performed using GraphPad
Prism 6 (GraphPad Software, San Diego, CA). Means were compared
using the two-tailed Student’s t test. p values of < 0.05 were considered
statistically significant.
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